Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 17, 2001
Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analoguesS Abgrall, I Charreau, V Joly, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1992
Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycosesL Saint-Julien, V Joly, M Seman, et al.
Presse Medicale (Paris, France : 1983)|May 30, 1992
[Choice and monitoring of the treatment of systemic mycoses. Value and limitations of in vitro tests]O Eloy, V Joly, J C Ghnassia, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1992
Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulationsV Joly, J Bolard, L Saint-Julien, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1988
Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenacV Joly, B Pangon, N Brion, et al.
Nephron|January 1, 1997
Evaluation of renal acidification in HIV-infected patients with hypergammaglobulinemiaM L Seux-Levieil, V Joly, P Yeni, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1991
Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in ratsP Longuet, V Joly, P Amirault, et al.
The European Respiratory Journal|September 6, 2002
Upregulation of nerve growth factor expression by human airway smooth muscle cells in inflammatory conditionsV Freund, F Pons, V Joly, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1994
Influence of diet on experimental toxicity of amphotericin B deoxycholateP Chavanet, V Joly, D Rigaud, et al.
British Journal of Anaesthesia|November 28, 2002
Esmolol prevents movement and attenuates the BIS response to orotracheal intubationC Menigaux, B Guignard, F Adam, et al.
Pageof 6